Romidepsin (FK228, Depsipeptide)

製品コードS3020 別名:FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide)化学構造

分子量(MW):540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

サイズ 価格(税別)  
JPY 26062.00
JPY 79182.00
JPY 115702.00

カスタマーフィードバック(5)

  • Concentration over time for each dose cohort of romidepsin (B).

    Blood, 2018, 131(4):397-407. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Impacts of chromopeptide A and FK228 on G2/M transition regulators. PC3 and LNCaP cells were treated with chromopeptide A or FK228 at indicated concentrations for 24 h, and cells lysates were immunoblotted with the indicated antibodies.

    Acta Pharmacol Sin, 2017, 38(4):551-560. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
特性 More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
ターゲット
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
体外試験

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 MorHR4VtdCCYaXHibYxqfHliQYPzZZk> MUCyMlUuOTVibl2= NF7Jdpc4OiCq NX3ycJhxcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MWWyOVc6ODlyNx?=
U2932  M{exUGNmdGxiVnnhZoltcXS7IFHzd4F6 MnzUNk42NTF3IH7N MYe3NkBp NEPveWZqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NVTySJJIOjV5OUC5NFc>
OCI-LY7 MULD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUeyMlUuOTVibl2= MYK3NkBp Ml;YbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NX:0XJduOjV5OUC5NFc>
Farage NWX6XGI4S2WubDDWbYFjcWyrdImgRZN{[Xl? M1LNdlIvPS1zNTDuUS=> Mon2O|IhcA>? M4XPZolv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NV3m[VRsOjV5OUC5NFc>
LY7/EBV MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MV6yMlUuOTVibl2= NIPTOpQ4OiCq M{nQNIlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? M4ThVVI2PzlyOUC3
U2932/EBV NYjUVGlbS2WubDDWbYFjcWyrdImgRZN{[Xl? MUOyMlUuOTVibl2= NHu3eXM4OiCq M4HPU4lv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NGLBWZgzPTd7MEmwOy=>
HCT116 M1HJVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPmOU02ODByIH7N NHjWTHEzPCCq MX3EUXNQ MWfpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= NXu4Sm4yOjV2OUK1NVU>
ACH-2 M3;U[mZ2dmO2aX;uJGF{e2G7 MknLNU06KG6P M2rjXlI1KGh? NWrsUHBXcW6mdXPld{BJUVZvMTDFcpYh\XiycnXzd4lwdg>? M2S5fVI2OTR7NE[3
MCF-10A MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rGVWlEPTB;MD6xO:KyOC5yMTDuUS=> NGfhd3IzPDl3NEi1Oi=>
MCF-7 NVTRU2d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XJXmlEPTB;MT6xNOKyOC5{MDDuUS=> M{TKSlI1QTV2OEW2
SK-BR-3 M{jyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jGdmlEPTB;MT6wNOKyOC5|NTDuUS=> MmPDNlQ6PTR6NU[=
MDA-MB-231 NWr3WG9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwNklCtVAvOTRibl2= NIjYeoUzPDl3NEi1Oi=>
PC3 MoTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTFwNkZCtVAvOzVibl2= NG\XV5czPDl3NEi1Oi=>
HCT116 M4X4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\EWWlEPTB;MT6wNOKyOC5yMDDuUS=> MnHKNlQ6PTR6NU[=
HCT116-p21-/- MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwMkdCtVAvOzdibl2= NWnpW21vOjR7NUS4OVY>
S1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHmUYVKSzVyPUeuOlfDuTBwMkmgcm0> NWTpU29OOjR7NUS4OVY>
SW620 M4f6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfmS|NKSzVyPUCuPVPDuTBwMkmgcm0> MYWyOFk2PDh3Nh?=
LOX-IMVI MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwOEhCtVAvODNibl2= MlnqNlQ6PTR6NU[=
UACC-62 M2DM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7kbGlKSzVyPUCuOVbDuTBwMU[gcm0> NH\3PI8zPDl3NEi1Oi=>
MDA-MB-435 NW[4T5RNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljhTWM2OD1yLkmwxtExNjB4IH7N NFH0S5kzPDl3NEi1Oi=>
SF-295 NVnBfXpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TRNmlEPTB;MD64POKyOC5zNTDuUS=> MlL3NlQ6PTR6NU[=
A549 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWm2TYVWUUN3ME2xMlI3yrFyLkK0JI5O NXPpfZVEOjR7NUS4OVY>
H460 NY\NXlVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HMOmlEPTB;Mj61POKyOC56MDDuUS=> NELlWlgzPDl3NEi1Oi=>
EKVX NX3uUZh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK1RXhKSzVyPUGuN|PDuTBwM{Sgcm0> NFiwVlczPDl3NEi1Oi=>
H146 NEDGcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO1TWM2OD1yLkKyxtExNjB5IH7N MXeyOFk2PDh3Nh?=
H526 NVvTcnJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMUZCtVAvODNibl2= M2LmdFI1QTV2OEW2
HuT-78 NGPZfJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUP0VXFSUUN3ME2xMlc{yrFyLkS0JI5O NVnHXnExOjR7NUS4OVY>
HA NHnu[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDoTYR6OC54MkWtNVBvVQ>? MYO0PEBp NVzKT|hzcW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? M4XPe|I1PzdzNUGw
MS-275 NGXkcmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYmwMlYzPS1zMH7N M3fZd|Q5KGh? NXvj[plXcW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? MoqwNlQ4PzF3MUC=
CD4 T MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULJZ2FiPDhiaB?= NUHYOVFYTUN3ME20MlXDuTFwMDDuUS=> M3\hcVI1PzJ{NEW0
CD4 T NGHYWHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV20PEBp NEDZZoJESzVyPUGwO:KyOTJ4IH7N NFrV[G0zPDd{MkS1OC=>
CD4+ T NHrle3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Lqb2VEPTB;MzDuUS=> MUSyOFQ6PTFyNR?=
A549 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPrUoRnOTEkgKOxNFDDqG6P MlLNNlQwOzZxNEigbC=> M13aSYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NEnmeXgzPDR6NUe5PS=>
JJN3 NEjB[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\OPIIzPC92ODDo NIHISoJGSzVyPEJihKlvVTtiNElihKlp MoDKNlQxOzBzNUC=
OPM-2 MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWWyOE81QCCq M3LzUmVEPTC|PUJihKlvVTtiNElihKlp MYWyOFA{ODF3MB?=
RPMI-8226 MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHLemp3OjRxNEigbC=> MW\FR|Uxez1zLklihKlvVTtiNElihKlp MnO5NlQxOzBzNUC=
U266 MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LzelI1NzR6IHi= MmfCSWM2OHN;MUFihKlvVTtiNElihKlp NFL4TZEzPDB|MEG1NC=>
CA46 NFrTbWdCeG:ydH;zbZMhSXO|YYm= M2DCUFYhcA>? NH7tfWFqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= M4X6cFI{QTZ4MU[0
DG75 MnjLRZBweHSxc3nzJGF{e2G7 MX[2JIg> M3PYbIlv\HWlZYOgco8h[XCxcITvd4l{ MkjYNlM6PjZzNkS=
Ramos M2\mR2Fxd3C2b4Ppd{BCe3OjeR?= MXe2JIg> MojwbY5lfWOnczDlfJRmdnOrdnWgZZBweHSxc3nz MUWyN|k3PjF4NB?=
ST486 MlXLRZBweHSxc3nzJGF{e2G7 NETzXYQ3KGh? NX;Zd4FEcW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{ NVTHZllrOjN7Nk[xOlQ>
HuT78 MorIRZBweHSxc3nzJGF{e2G7 MXOxM|ExNzFyMDDuUS=> MWe0PEBp NIXwZYJqdmS3Y3XzJIFxd3C2b4Ppd{BifCBzIH7N NXXNSZNJOjN3M{K3N|I>
DpVp35 MkPiRZBweHSxc3nzJGF{e2G7 NVHO[IhWOS9zMD:xNFAhdk1? MmnEOFghcA>? MoixbY5lfWOnczDicJVvfCCjcH;weI9{cXN? MWGyN|U{Ojd|Mh?=
DpVp50 NEDBSWhCeG:ydH;zbZMhSXO|YYm= NYPmVVNTOS9zMD:xNFAhdk1? M{DNUVQ5KGh? MYPpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? NHL2XWwzOzV|MkezNi=>
DpP75  M3eyTGFxd3C2b4Ppd{BCe3OjeR?= Ml;wNU8yOC9zMECgcm0> NIjhU3M1QCCq MXzpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? NEjUXXQzOzV|MkezNi=>
SKOV-3 NHLNRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4mzfVHjiJN{MH7N M1zIdVczKGh? MkDiSG1UVw>? M4G2N5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv MkjRNlMxOTB|NEi=
Brca1 WT MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzHS3cyOeLCk{Kwcm0> MmrPO|IhcA>? M3XRTWROW09? NF\Id|Vz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? MnPrNlMxOTB|NEi=
Brca1 Null NYnDWFZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnsNgKBmzJybl2= NHTZNJg4OiCq MV7EUXNQ M1LIc5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv MYSyN|AyODN2OB?=
OVCAR-8  MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXWx5qCUOjCwTR?= MYK3NkBp M4rzWWROW09? NVTKUVZ4emWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? NWTKWnhkOjNyMUCzOFg>
NCI/ADR-RES M3raTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHUOoJUOeLCk{Kwcm0> MYK3NkBp MXfEUXNQ NGjjUZRz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NUDYSmJ[OjNyMUCzOFg>
HCT116 NHLlW|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnwSYdpPSCwTT21NEDPxE1? NHPGWmMzPCCq MmfJSG1UVw>? NYrYSoVTcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NUDVPI5WOjJ7MkS5OVg>
RKO Mor1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[2OUBvVS13MDFOwG0> NXHXVm1VOjRiaB?= MVrEUXNQ MUHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> Mm\wNlI6OjR7NUi=
CO115 NIHuNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUG1JI5ONTVyIN88US=> NFOxZXQzPCCq M{nsXGROW09? NYDUZ2ZFcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? Ml;sNlI6OjR7NUi=
HFS MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILvTm82KG6P MVeyOE81QC95MjDo Mnu0bY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> NG\UUVkzOjFyNkK4Ni=>
LNCaP MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHzdHQ{PSCwTR?= NHy0R5QzPC92OD:3NkBp Ml\1bY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> MUOyNlExPjJ6Mh?=
A549 M{m0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX5RlhsPSCwTR?= NFH4dnozPC92OD:3NkBp NELQSZNqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 MmnkNlIyODZ{OEK=
697  Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjjW5AxUUN3MPMAjV3jiIl{LkZCpI5O MVqyNVU{QDJzNh?=
697-R MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGSzdWJKSzVy4pEJQgKBkThwNtMgcm3DqA>? MViyNVU{QDJzNh?=
HUT78 NHWxUnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFibl2= NF;oTmEzOTF7OEW0OS=>
THJ-16T MmL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjEXoxsOSCwTR?= MofTNlQhcA>? NH;VXHJqdmirYnn0d{Bk\WyuIHfyc5d1cA>? NHe5[lAzODhzMEW2PC=>
HCT116 MWHGeY5kfGmxbjDBd5NigQ>? M3y1cVIxKG6P NEDhXXI5KGh? MYHtc4R2dGG2ZYOgeJJidnOlcnnweEBt\X[nbIOg[o9zKGi3bnTy[YR{KG:oIHflcoV{KGmwIHXpeIhmeiCmaYLlZ5Rqd25? NGLjXHUzODd|OUS1OC=>
B104  M2rtc2Z2dmO2aX;uJGF{e2G7 NYHwUmNNOiCwTR?= MX2yOE81QC95MjDo NVXpSlNZcW6lcnXhd4V{KHSqZTDzeZJn[WOnIHX4dJJme3Orb36gc4YhS0R{MNMg M4noeFIxPjh4NUC1
HL-60  MW\DfZRwfG:6aXPpeJkhSXO|YYm= NGD6WGwyNTVyMDDuUS=> MnLtNlQhcA>? NFnkfW5qdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NGLRXIgzODZ{NEG2Ny=>
HP100 NI\peZVEgXSxdH;4bYNqfHliQYPzZZk> M2jNdlEuPTByIH7N MXiyOEBp M{PNOYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NVTWOIFTOjB4MkSxOlM>
HL-60  NHTzOnVHfW6ldHnvckBCe3OjeR?= MmC5NVAhdk1? NWXEVlg5PC94L{G2JIg> M4nwbolv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?= NFj0VZAzODZ{NEG2Ny=>
HP100 M2LZNWZ2dmO2aX;uJGF{e2G7 NFTDWJgyOCCwTR?= MkW2OE83NzF4IHi= NIW5Z4dqdmS3Y3XzJJRp\SCpZX7ldoF1cW:wIH;mJIh6\HKxZ3XuJJBmem:6aXTlJIZzd21iNHi= NXqwN3FXOjB4MkSxOlM>
HL-60  MlGzSpVv[3Srb36gRZN{[Xl? NFTiO4wyOC13MECgcm0> MVi0JIg> MYDk[YNz\WG|ZYOgeIhmKGirc4TvcoUh\GWjY3X0fYxie2ViKFjERWMqKGGldHn2bZR6yqB? NIPwUIszODZ{NEG2Ny=>
HP100 MkD3SpVv[3Srb36gRZN{[Xl? M{X5ZlExNTVyMDDuUS=> NYHXRXJRPCCq M4TOdIRm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= NHPmeXkzODZ{NEG2Ny=>
11z M{\zXWtqdmG|ZTDBd5NigQ>? MnSwN{0yODBibl2= M2nqTJJm\HWlZYOgTGRCSyCnbor5cYF1cWNiYXP0bZZqfHliKFnDOVDDqD1iNj61JOKyKDBwNjDucY9tN0xr M4Tw[|IxPjB3MUS0
SKOV-3 MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[0M|gwOTZibl2= NH;abYc1QCCq MWPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MlX5NlA1ODR3NkS=
OVCAR-3 MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7RbHI1NzhxMU[gcm0> MVy0PEBp MmW3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> Mny5NlA1ODR3NkS=
HBL-2 NInkUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYmyMVExKG6P MmXRNlQhcA>? MmrmTWM2OD12LkOgcm0> M1zrfFIxODZ6MEiw
Jeko-1 MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fnZ|IuPTBibl2= NVPzeY1KOjRiaB?= M2XTbWlEPTB;MUGgcm0> MYKyNFA3QDB6MB?=
Granta-519 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVO1MVQxKG6P NG\1[pMzPCCq MWXJR|UxRTV6LkWgcm0> MXKyNFA3QDB6MB?=
L1236 NGD3[JhEgXSxdH;4bYNqfHliQYPzZZk> MWixJI5ONTFyMDFOwG0> M2PKOlQ5KGh? MnO1SWM2OD1yLkC3JO69VQ>? MX[xPVI{OzR5MB?=
L428 M37lbmN6fG:2b4jpZ4l1gSCDc4PhfS=> MlnJNUBvVS1zMECg{txO NYX3bpNLPDhiaB?= NYK0SGU1TUN3ME2wMlQ{KM7:TR?= NIO2eFkyQTJ|M{S3NC=>
KM-H2 MUDDfZRwfG:6aXPpeJkhSXO|YYm= MXKxJI5ONTFyMDFOwG0> NV7SNng2PDhiaB?= NX7aN4s{TUN3ME2wMlU5KM7:TR?= NULCR3YyOTl{M{O0O|A>
L540Cy M4TyOmN6fG:2b4jpZ4l1gSCDc4PhfS=> NHnDdZIyKG6PLUGwNEDPxE1? MontOFghcA>? M13FU2VEPTB;MD6xOkDPxE1? NED4NIwyQTJ|M{S3NC=>
G401 NGL6b3dHfW6ldHnvckBCe3OjeR?= M{jPcFExKG6P NUexe2xkOjRxNEivO|IhcA>? M3W1bWROW09? NUPR[llYcW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v M{e5[VE6OjJzNUi2
STM91-01 M{ToVGZ2dmO2aX;uJGF{e2G7 M{\PR|ExKG6P NGPJTFkzPC92OD:3NkBp NYfOcFg2TE2VTx?= NGXhZZlqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> M3Ox[|E6OjJzNUi2
SJSC  NVjRe|ZrTnWwY4Tpc44hSXO|YYm= NFPQXowyOCCwTR?= MXeyOE81QC95MjDo MlKySG1UVw>? MXPpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= MkTzNVkzOjF3OE[=
BT16  NX\iUY9QTnWwY4Tpc44hSXO|YYm= M1i2S|ExKG6P M1PZWlI1NzR6L{eyJIg> M2fPZ2ROW09? Mlr6bY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u NX75VZZJOTl{MkG1PFY>
NCI-H1299 MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYK2WXJTUUN3ME20MlbDuTBwMjDu[{9udA>? M2jWdFE6OTd7OEmw
NCI-2882 M3XXZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofwTWM2OD1zLkdCtVAvODRibnevcYw> NI\ne4oyQTF5OUi5NC=>
HCC95 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXVZ3BKSzVyPUKuOeKyOC5yNTDu[{9udA>? MnfZNVkyPzl6OUC=
NCI-H23 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjSOJBKSzVyPUKuPeKyOC5{IH7nM41t NUn1VY1xOTlzN{m4PVA>
NCI-H157 MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGOxboZKSzVyPUGuOuKyOC5yMjDu[{9udA>? M3LSOlE6OTd7OEmw
NCI-H460 NVTEeo5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnWO2VKSzVyPUKuNeKyOC5yNzDu[{9udA>? NVT0PFZZOTlzN{m4PVA>
NCI-H1975 NXrr[JlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPvR3RKSzVyPUGuN:KyOC5yNDDu[{9udA>? MX[xPVE4QTh7MB?=
NCI-H820 NGj1[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJwNNMxNE4yKG6pL33s M3zoTVE6OTd7OEmw
NCI-H1650 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTRwOdMxNE4{KG6pL33s MVKxPVE4QTh7MB?=
DTC1 NXjmOIxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknYTWM2OD1yLkWxJI5O MlnQNVg2PjZ{NE[=
KAO NWDBZ|NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwOUGgcm0> NI\5VpEyQDV4NkK0Oi=>
SU-CCS-1 NX;rWXd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfEN3VHUUN3ME2wMlg6KG6P MnLoNVg2PjZ{NE[=
SYO-1 MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzVTWM2OD1yLk[3JI5O MUWxPFU3PjJ2Nh?=
FUJI MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7rToRKSzVyPUGuN|Ehdk1? MlXSNVg2PjZ{NE[=
SKNMC M4\Jemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\1RmlEPTB;MT6xO{BvVQ>? NIryPI0yQDV4NkK0Oi=>
402-91 M2TNR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XvSmlEPTB;MT6yOkBvVQ>? NXqxPGtEOTh3Nk[yOFY>
1765-92 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;vTWM2OD1zLke3JI5O NYLiNVN1OTh3Nk[yOFY>
JN-DSRCT-1 M1W1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfWVGZKSzVyPUGuNlUhdk1? NFzrRnQyQDV4NkK0Oi=>
NMS-2PC NU\GSIVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX5TWM2OD1yLkixJI5O Mn70NVg2PjZ{NE[=
HL60 NHO0O|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXRTWM2OD1zLki2JI5O NHmyUmoyQDV4NkK0Oi=>
A549 M4K4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r4eWlEPTB;Mz6yOEBvVQ>? MYexPFU3PjJ2Nh?=
SW480 MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYH6WZR7UUN3ME2yMlY6KG6P MW[xPFU3PjJ2Nh?=
MCF7 MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X6WGlEPTB;Mz61OUBvVQ>? M{LzbVE5PTZ4MkS2
PC-3 NEDEOllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O0fWlEPTB;Mj61NUBvVQ>? NVPHbZU6OTh3Nk[yOFY>
MMRU NUfndGd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Pp[mlEPTB;Mj61O{BvVQ>? MkLrNVg2PjZ{NE[=
Hs68 NH7hdlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\H[mlEPTB;PkGwJI5O NIrCO4MyQDV4NkK0Oi=>
hMSC-001F NFTCcHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvBTWM2OD1-MUCgcm0> MXOxPFU3PjJ2Nh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
細胞試験:

[3]

+ 展開
  • 細胞株: HL60, Jurkat, A549, and MCF-7
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (参考用のみ)
動物試験:

[5]

+ 展開
  • 動物モデル: Male scid mice inoculated i.p. with U-937 cells
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~1 mg/kg once or twice a week
  • 投与方法: Treated i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 540.7
化学式

C24H36N4O6S2

CAS No. 128517-07-7
保管
in solvent
別名 FR 901228, NSC 630176

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03703375 Not yet recruiting Lymphoma T-Cell Celgene October 15 2018 Phase 3
NCT03547700 Recruiting Lymphoma T-Cell Peripheral Ryan Wilcox|University of Michigan Cancer Center|Takeda|Big Ten Cancer Research Consortium September 26 2018 Phase 1|Phase 2
NCT03355768 Not yet recruiting Lymphoma T-Cell Peripheral Jennifer Amengual|Columbia University September 2018 Phase 3
NCT03593018 Not yet recruiting Relapsed Angioimmunoblastic T-Cell Lymphoma|Refractory Angioimmunoblastic T-cell Lymphoma The Lymphoma Academic Research Organisation|Celgene September 2018 Phase 3
NCT03161223 Recruiting Lymphoma T-Cell Columbia University|University of Bologna|Samsung Medical Center|Celgene June 1 2018 Phase 1|Phase 2
NCT03432741 Recruiting Breast Adenocarcinoma|Recurrent Breast Carcinoma|Recurrent Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Nodal Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IV Breast Cancer AJCC v6 and v7 Mayo Clinic|National Cancer Institute (NCI) March 27 2018 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Romidepsin (FK228, Depsipeptide)を買う | Romidepsin (FK228, Depsipeptide) ic50 | Romidepsin (FK228, Depsipeptide)供給者 | Romidepsin (FK228, Depsipeptide)を購入する | Romidepsin (FK228, Depsipeptide)費用 | Romidepsin (FK228, Depsipeptide)生産者 | オーダーRomidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)化学構造 | Romidepsin (FK228, Depsipeptide)分子量 | Romidepsin (FK228, Depsipeptide)代理店
×

春節(旧正月)休暇に伴う納期遅延のお知らせ
上海工場が春節休業となるため、輸入が必要な製品の納期が通常より2週間ほど遅れます。
1月25日までにご注文いただきました製品は通常通り出荷させていただきます。1月28日-2月8日にご注文いただいた製品は2月19日以降の出荷となります。ご不便をおかけいたしますが、何卒ご理解くださいますようお願い申し上げます。

×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID